While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Shares in Google-parent Alphabet (GOOGL, GOOG) tumbled in after-hours trading following the release of the tech giant's ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...